Tome Biosciences emerged from stealth with $213 million in financing and plans to create curative cell and gene therapies that correct genes in vivo. The company’s programmable genomic integration technology enables the insertion of any DNA sequence into any programmed genomic location. Initial projects include gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases. The company, which has almost 150 employees, plans to disclose clinical indications for its first therapies in 2024.
Tata Electronics cyber incident underscores need for stronger AI-era data protection – EdexLive
Tata Electronics cyber incident underscores need for stronger AI-era data protection EdexLive
